摘要
目的:探讨奥沙利铂联合替吉奥(SOX方案)和吉西他滨联合顺铂(GP方案)对晚期三阴乳腺癌患者临床疗效及糖类抗原153(CA153)、癌胚抗原(CEA)水平的影响。方法:选取2012年8月至2015年8月盐城市第一人民医院的134例晚期三阴乳腺癌患者作为研究对象,根据随机数字表法分为A组和B组,每组各67例,A组患者给予SOX方案治疗,B组患者给予GP方案治疗,对比分析两组患者近期疗效、远期疗效、不良反应以及血清CA153和CEA水平。结果:A组患者总有效率(RR)和疾病控制率(DCR)分别为35.82%和68.66%,B组患者RR和DCR分别为34.33%和65.67%,两组差异均无统计学意义(P>0.05);A组和B组患者中位疾病进展时间分别为9.7个月和8.2个月,差异具有统计学意义(P=0.031);A组和B组患者1年生存率分别为70.15%和64.18%,差异无统计学意义(P=0.462);A组和B组患者中位总生存时间分别为20.1个月和19.4个月,差异无统计学意义(P=0.289)。两组患者常见不良反应相似,其中A组患者手足综合征、肝功能损伤、腹泻以及外周神经毒性发生率分别为44.78%、46.27%、40.30%和58.21%,均显著高于B组患者(分别为0、23.88%、17.91%和14.93%),差异均有统计学意义(P<0.05);A组患者皮疹、恶心/呕吐、血小板降低和肾脏毒性发生率分别为19.40%、41.79%、41.79%和7.46%,均显著低于B组患者(分别为37.31%、70.15%、65.67%和28.36%),差异均有统计学意义(P<0.05);治疗后,两组患者CA153、CEA水平与治疗前相比均显著降低,差异具体统计学意义(P<0.05);且治疗后两组患者CA153、CEA水平比较,差异均无有统计学意义(P>0.05)。结论:临床晚期三阴乳腺癌患者采用SOX方案和GP方案治疗,均可取得理想疗效,且耐受性较好。
Objective： To explore the effects of Oxaliplatin plus S-1（SOX） and Gemcitabine plus Cisplatin（GP）regimens on advanced triple-negative breast cancer patients and its affection on levels of carbohydrate antigen 153（CA153） and carcinoembryonic antigen（CEA）.Methods： 134 patients with advanced triple-negative breast cancer treated in Yancheng City First People＇s Hospital from August 2012 to August 2015 were selected,and divided into group A and group B（67 cases in each group）.Group A was treated with SOX regimen,and group B was treated with GP regimen.The short term effect,long term curative,adverse reactions,serum CA153 and CEA levels were compared between the two groups.Results： After treatment,the response rate and disease control rate of group A was 35.82% and 68.66%,and group B was 34.33% and 65.67%,the difference was not statistically significant（P〈0.05）.The median time to progression was 9.7 months in group A and 8.2 months in group B,the difference between the two groups was statistical significantly（P = 0.031）.The 1-year survival rates was 70.15% in group A and 64.18% in group B,the difference was not statistically significant（P = 0.462）.The median time to overall survival was 20.1 months in group A and 19.4 months in group B,the difference was not statistically significant（P = 0.289）.Adverse reactions were similar between the two groups.The incidence of hand-foot syndrome,liver function damage,diarrhea and peripheral nerve toxicity in group A were 44.78%,46.27%,40.30% and58.21%,were significantly higher than those in group B（0,23.88%,17.91% and 14.93%）,the difference between the two groups was statistically significant（P〈0.05）.The incidence of skin rash,nausea/vomiting,thrombocytopenia and renal toxicity in group A were 19.40%,41.79%,41.79% and 7.46%,were significantly lower than those in group B（37.31%,70.15%,65.67% and 28.36%）,the difference between the two groups was statistically significant（P〈0.05）.After treatment,the levels of CA135 and CEA of the two groups were significantly reduced compared with before,the difference was statistically significant（P〈0.05）.And the levels of CA135 and CEA of two groups had no statistically significant difference after treatment（P〈0.05）.Conclusion： Both SOX and GP regimens are safe,effective and tolerable in reating advanced triple-negative breast cancer patients.
出处
《东南大学学报（医学版）》
CAS
北大核心
2017年第5期728-734,共7页
Journal of Southeast University(Medical Science Edition)
关键词
奥沙利铂
吉西他滨
顺铂
三阴乳腺癌
糖类抗原153
癌胚抗原
Oxaliplatin
Gemcitabine
Cisplatin
triple-negative breast cancer
carbohydrate antigen 153
carci- noembryonic antigen
